Literature DB >> 9811332

In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms.

J W Mandell1, I M Hussaini, M Zecevic, M J Weber, S R VandenBerg.   

Abstract

Abnormal growth factor signaling is implicated in the pathogenesis of gliomas. The extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway is a likely target, linking receptor tyrosine kinase activation to downstream serine/threonine phosphorylation events regulating proliferation and differentiation. Signaling within heterogeneous cell populations of gliomas cannot be adequately assessed by traditional biochemical enzyme assays. Immunohistochemical detection of doubly phosphorylated (activated) ERK/MAPK permitted visualization of spatially discrete cellular patterns of ERK/MAPK activation, compared with the relatively uniform expression of total ERK/MAPK protein. The astrocytic tumors, regardless of grade, had the highest overall degree of enzyme activation, whereas oligodendrogliomas had the least. Anaplastic progression in oligodendrogliomas resulted in a larger number of cells with active ERK/MAPK. Within glioblastomas, microvascular hyperplasia and necrosis were associated with ERK/MAPK activation in adjacent tumor cells. In addition to spatial patterns of intratumor paracrine signaling, a possible cell-cycle-associated regulation was detected: mitotic and actively cycling tumor cells showed diminished activation relative to cells in G0. Although ERK/MAPK activation was not restricted to neoplastic glia, consistent patterns of selective activation in tumor cells suggests that sustained activation may contribute to the neoplastic glial phenotype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811332      PMCID: PMC1853399          DOI: 10.1016/S0002-9440(10)65728-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  BDNF-activated signal transduction in rat cortical glial cells.

Authors:  J D Roback; H N Marsh; M Downen; H C Palfrey; B H Wainer
Journal:  Eur J Neurosci       Date:  1995-05-01       Impact factor: 3.386

Review 2.  The mitogen-activated protein kinases, ERK1 and ERK2.

Authors:  M H Cobb; J E Hepler; M Cheng; D Robbins
Journal:  Semin Cancer Biol       Date:  1994-08       Impact factor: 15.707

3.  MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos.

Authors:  K Okazaki; N Sagata
Journal:  Oncogene       Date:  1995-03-16       Impact factor: 9.867

Review 4.  Platelet-derived growth factor in human glioma.

Authors:  B Westermark; C H Heldin; M Nistér
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

5.  Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas.

Authors:  M Hermanson; K Funa; J Koopmann; D Maintz; A Waha; B Westermark; C H Heldin; O D Wiestler; D N Louis; A von Deimling; M Nistér
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

Review 6.  Genetic alterations associated with the evolution and progression of astrocytic brain tumours.

Authors:  H Ohgaki; B Schäuble; A zur Hausen; K von Ammon; P Kleihues
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor.

Authors:  R B Montgomery; D K Moscatello; A J Wong; J A Cooper; W L Stahl
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

8.  Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.

Authors:  H Oka; Y Chatani; R Hoshino; O Ogawa; Y Kakehi; T Terachi; Y Okada; M Kawaichi; M Kohno; O Yoshida
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

Review 9.  Molecular genetics of human glioma.

Authors:  B Westermark; M Nistér
Journal:  Curr Opin Oncol       Date:  1995-05       Impact factor: 3.645

10.  Constitutive phosphorylation of Shc proteins in human tumors.

Authors:  G Pelicci; L Lanfrancone; A E Salcini; A Romano; S Mele; M Grazia Borrello; O Segatto; P P Di Fiore; P G Pelicci
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

View more
  31 in total

Review 1.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

Authors:  James W Mandell
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

2.  Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Authors:  David Schiff; Kurt A Jaeckle; S Keith Anderson; Evanthia Galanis; Caterina Giannini; Jan C Buckner; Phillip Stella; Patrick J Flynn; Bradley J Erickson; John F Schwerkoske; Vesna Kaluza; Erin Twohy; Janet Dancey; John Wright; Jann N Sarkaria
Journal:  Cancer       Date:  2018-01-03       Impact factor: 6.860

3.  Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor.

Authors:  Martin Köbel; Gudrun Pohl; Wolfgang D Schmitt; Steffen Hauptmann; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

4.  Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.

Authors:  Angelica A Saetta; Georgia Levidou; Elias A El-Habr; Ioannis Panayotidis; Vassilis Samaras; Irene Thymara; Stratigoula Sakellariou; Efstathios Boviatsis; Efstratios Patsouris; Penelope Korkolopoulou
Journal:  Virchows Arch       Date:  2011-04-15       Impact factor: 4.064

5.  The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats.

Authors:  Chengkai Dai; Yelena Lyustikman; Alan Shih; Xiaoyi Hu; Gregory N Fuller; Marc Rosenblum; Eric C Holland
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

Review 6.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

7.  Effects of MAP kinase inhibitors on epidermal growth factor-induced neoplastic transformation of human keratinocytes.

Authors:  Hideya Mizuno; Yong-Yeon Cho; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-01       Impact factor: 4.784

8.  The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinoma.

Authors:  Simone de Leon Martini; Carolina Beatriz Müller; Rosalva Thereza Meurer; Marilda da Cruz Fernandes; Rodrigo Mariano; Mariel Barbachan E Silva; Fábio Klamt; Cristiano Feijó Andrade
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

9.  Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.

Authors:  Shigeo Ohba; Yuichi Hirose; Takeshi Kawase; Hirotoshi Sano
Journal:  J Neurooncol       Date:  2009-06-11       Impact factor: 4.130

10.  Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation.

Authors:  Adriana Handra-Luca; Hadi Bilal; Jacques-Charles Bertrand; Pierre Fouret
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.